<DOC>
	<DOCNO>NCT00671060</DOCNO>
	<brief_summary>The purpose propose study test - randomize , blind trial - two different dos prostaglandin E1 analogue misoprostol administer buccally treatment fetal death 14 - 28 week , inclusive , pregnancy . At advanced stage pregnancy , nonviable fetus often spontaneously evacuate , yet timely evacuation vital order avoid possibility , among thing , potentially life-threatening maternal coagulopathies . Current approach uterine evacuation case include dilatation evacuation ( D &amp; E ) surgery ( less advanced pregnancy ) labor induction variety product . Misoprostol demonstrate effective , effective , either oxytocin prostaglandin E2 analogues indication number small , non-FDA-approved trial publish peer-reviewed literature . In absence formal study treatment , however , dosage standardize , pathway administration vary , uncertainty linger . The purpose protocol propose herein formally establish , via randomize , double-blinded study , safety effectiveness misoprostol indication , compare value two distinct dos , provider may henceforward proceed great authority confidence .</brief_summary>
	<brief_title>Misoprostol Treatment Fetal Death 14-28 Weeks Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>Fetal Death</mesh_term>
	<mesh_term>Stillbirth</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Women present spontaneous fetal death Gestational age fetus 1428 week Transmural uterine scar ; Allergies contraindication use misoprostol ; Placental abruption active hemorrhage ; Complete placenta previa ; Extreme uterine structural anomaly ; Or contraindication vaginal delivery fetus ; Presentation active labor ( moderate severe contraction every 10 minute ) ; Four previous delivery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>intrauterine fetal death</keyword>
	<keyword>misoprostol</keyword>
</DOC>